Scope
- Safety Remove Safety filter
- Epidemiology (3) Apply Epidemiology filter
- Pharmacovigilance (3) Apply Pharmacovigilance filter
- Public Administration (3) Apply Public Administration filter
- Therapy (3) Apply Therapy filter
- Quality of care research (2) Apply Quality of care research filter
- Biovigilance (1) Apply Biovigilance filter
- Diagnosis (1) Apply Diagnosis filter
- Efficacy (1) Apply Efficacy filter
- Pharmacoeconomic (1) Apply Pharmacoeconomic filter
- Pharmacogenetic (1) Apply Pharmacogenetic filter
- Pharmacogenomic (1) Apply Pharmacogenomic filter
Commissioners
- National Institute for Health and Disability Insurance (3) Apply National Institute for Health and Disability Insurance filter
- Andrew Cunningham (1) Apply Andrew Cunningham filter
- Anouk Waeytens (1) Apply Anouk Waeytens filter
- Calidos (1) Apply Calidos filter
- European Monitoring Centre for Drugs and Drug Addiction (1) Apply European Monitoring Centre for Drugs and Drug Addiction filter
- Federal Agency for Medicines and Health Products (1) Apply Federal Agency for Medicines and Health Products filter
- Federal Public Service Health, Food Chain Safety and Environment - cell quality and patient safety (1) Apply Federal Public Service Health, Food Chain Safety and Environment - cell quality and patient safety filter
- Federal Service Public Health - cell quality and patient safety (1) Apply Federal Service Public Health - cell quality and patient safety filter
- GZA hospitals (1) Apply GZA hospitals filter
- Interministerial Conference of Public Health (1) Apply Interministerial Conference of Public Health filter
- Kurt Doms (1) Apply Kurt Doms filter
Careprovider
- General hospitals (4) Apply General hospitals filter
- Laboratories: clinical biology (2) Apply Laboratories: clinical biology filter
- Psychiatric hospitals (2) Apply Psychiatric hospitals filter
- University hospitals (2) Apply University hospitals filter
- Unknown (2) Apply Unknown filter
- Laboratories: anatomical pathology (1) Apply Laboratories: anatomical pathology filter
- Laboratories: human genetics (1) Apply Laboratories: human genetics filter
Caregiver
Sponsors
- National Institute for Health and Disability Insurance (3) Apply National Institute for Health and Disability Insurance filter
- Andrew Cunningham (1) Apply Andrew Cunningham filter
- Federal Public Service Health, Food Chain Safety and Environment (1) Apply Federal Public Service Health, Food Chain Safety and Environment filter
- Federal Public Service Health, Food Chain Safety and Environment - cell quality and patient safety (1) Apply Federal Public Service Health, Food Chain Safety and Environment - cell quality and patient safety filter
- Kurt Doms (1) Apply Kurt Doms filter
- Peter Blanckaert (1) Apply Peter Blanckaert filter
- Xavier De Cuyper (1) Apply Xavier De Cuyper filter
Support
- National Institute for Health and Disability Insurance (4) Apply National Institute for Health and Disability Insurance filter
- Federal Agency for Medicines and Health Products (FAMHP) (1) Apply Federal Agency for Medicines and Health Products (FAMHP) filter
- Federal Public Service Health, Food Chain Safety and Environment - cell quality and patient safety (1) Apply Federal Public Service Health, Food Chain Safety and Environment - cell quality and patient safety filter
Registration projects in health and health care
Female genital prolapse is characterized by a portion of the vaginal canal protruding (prolapsing) the opening of the vagina. This can be treated by placing vaginal mesh devices via either the abdominal or vaginal way. The standard procedure is via the abdominal canal as this is generally associated with less side effects.
However, in specific conditions (anterior or apical prolapse), the vaginal procedure can be less risky than the abdominal procedure and should therefore be preferred.
The commission de remboursement des implants et des dispositifs medicaux invasifs (...
The BEWSD database collects information regarding the analysis of illicit drug samples (both known illicit drugs and new psychoactive substances) in Belgium.This concerns mostly analytical data regarding dosage/purity/contaminants of seized powders, tablets, etc. In the future, also clinical toxicological data will be added, describing intoxications with known illicit drugs or new psychoactive substances, originating from the clinical toxicology laboratories in Belgium.
In 2012 a limited use case was carried out in which five hospitals participated on a voluntary basis.
These hospitals have all incident reports from 3 random months to the deepest level
coded according to the International Classification for Patient Safety of the WHO (ICPS).
After the experience with the limited usecase with 5 hospitals, the next step is a broad aggregation of
adverse events in Belgium under the motto: 'aggregation of adverse events to learn'.
UREG est un système d'enregistrement de données en real-time centré sur les services d'urgences agréés des hôpitaux de Belgique. Les données doivent être enregistrées sur base continue et en temps réel pour tous les patients se trouvant dans les services d'urgences.
UREG is een registratiesysteem voor gegevens van de erkende spoedgevallendiensten van de Belgische ziekenhuizen. De gegevens worden op een continue basis in real time geregistreerd voor alle patiënten die zich op deze spoedgevallendiensten aanmelden.
No information available